Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyCentene definitive drug testing Coverage Update | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedCentenePolicy CP.MP.50

    Drugs of Abuse: Definitive Testing

    Customize your policy alerts

    Sign up for Centene Policy CP.MP.50 alerts

    Get alerted when Policy CP.MP.50 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Outpatient definitive/confirmatory (quantitative) drug testing for drugs of abuse in urine and other specimens, governing medical necessity criteria, coding implications, and exclusions for Centene-affiliated health plans.

    Policy Summary
    PayerCentene
    PolicyDrugs of Abuse: Definitive Testing
    Policy CodePolicy CP.MP.50
    Change TypeCriteria and coding updatesauthorization protocol added
    Effective Date
    Next Review Date
    Key ActionObtain a presumptive test before ordering definitive testing unless no reliable presumptive test exists; submit PA within 10 business days when required (children ≤6 exempt).
    SourceLink
    POLICY UPDATE CHANGES

    Modified criteria to require a presumptive test before a definitive test unless no reliable test is in existence.

    HCPCS codes G0482 and G0483 were stated as not supporting coverage criteria; G0480 and G0481 support coverage criteria.

    Authorization protocols added: testing for children 6 years of age is exempt from authorization and PA requests accepted up to 10 business days after specimen collection.

    Presumptive drug testing criteria removed from this policy and moved to a separate policy (CP.MP.208).

    <14Drugs/drug classes allowed for confirmatory testing when meeting criteria
    10 daysAuthorization requests window
    Children ≤6PA exemption
    G0480, G0481HCPCS codes that support coverage
    G0482, G0483HCPCS codes not supporting coverage
    MultipleCoding references

    Coverage Criteria

    Covered: Confirmatory/Definitive Testing

    Covered when ALL of the following are met (criteria grouped A, B, or C):

    Overall pathways: Coverage allowed when criteria set A OR B OR C is met

    See children exemption and authorization timing separately

    A: When a preliminary/presumptive test has been performed: (1) Documented history or suspicion of illicit or prescription misuse, noncompliance, or high probability of non-adherence documented in the medical record; (2) A preliminary/presumptive drug test has been previously performed unless no reliable test exists (e.g., synthetic cannabinoids); (3) The preliminary/presumptive test result is inconsistent with expected results based on medical history, clinical presentation, or patient statement OR the result is consistent but drug class–specific assays are needed to identify the precise drug(s); (4) Resolving the inconsistency is essential to ongoing care; (5) Requested confirmatory tests are for fewer than 14 drugs/drug classes and only for the specific drugs/drug classes indicated by the preliminary analysis; (6) Specific substance and/or quantity information is desired.<14 drugs/drug classes

    Derived from policy A sequence

    B: Provider expects presumptive test to be positive: (1) Provider expects a positive presumptive test (e.g., patient reports recent use); (2) There are established clinical decision-making benchmarks based on specific substance and/or quantitative levels; (3) Requested tests are for fewer than 14 drugs/drug classes; (4) Tests are only for specific drugs/drug classes expected to be positive.<14 drugs/drug classes

    Derived from policy B sequence

    C: Serum therapeutic level testing: Request is for a serum therapeutic level in relation to medical treatment of a disease or condition (e.g., phenobarbital level for seizure treatment).

    Covers therapeutic drug monitoring requests

    Definitive Testing: Coverage Criteria (overview)

    Covered when testing meets definitive method requirements and when one of the medical necessity conditions is met; presumptive testing generally required prior to definitive testing unless no reliable presumptive test exists.

    Definitive method requirements: Definitive testing must utilize methods able to identify individual drugs and distinguish structural isomers (e.g., GC-MS, LC-MS) with stable isotope/internal standards and method- or drug-specific calibration and matrix-matched quality control; includes specimen validity testing.per HCPCS code class counts

    See HCPCS G0480/G0481 descriptions

    Medical necessity gating: One of the medical necessity conditions specified in section I must be met (policy text clarifies a presumptive test is generally required before definitive testing unless no reliable presumptive test exists).N/A

    Presumptive test required before definitive testing unless no reliable presumptive test exists

    Not medically necessary: Excessive number of tests

    Excessive multi-class testing: Outpatient confirmatory/definitive quantitative drug testing of more than 14 drugs/drug classes is not medically necessary.>=14 drugs/drug classes

    Explicit policy statement

    Not medically necessary: Administrative and other exclusions

    Administrative exclusions: Testing performed for employment/pre-employment or continuation of employment, school or community athletic participation, medico-legal/court-ordered screening (unless required by state regulations), routine physicals, administrative exams (marriage, licensure, insurance), and similar administrative reasons is considered not medically necessary.

    List is illustrative per policy

    Laboratory/process exclusions: Same-day multi-source screening across blood, saliva, and urine; reflex definitive testing when presumptive testing is performed at point of care; performing presumptive immunoassay screening and ordering presumptive IA testing from a reference laboratory without appropriate physician order; IA testing used to 'confirm' a CLIA-waived presumptive result; and specimen validity/adulteration testing performed as laboratory QC are not covered or are excluded per policy.

    Operational exclusions

    Testing performed for administrative purposes is considered not medically necessary. This includes screening required as a condition of employment or pre-employment, for continuation of employment, for school or community athletic participation, and for medico-legal or court-ordered screening unless the screening is specifically required by state regulation. Routine physicals, administrative exams (for example marriage, licensure, or insurance evaluations), and similar non-clinical uses are likewise excluded.

    The following scenarios are explicitly listed as not medically necessary and may trigger claim denials: blanket orders or routine standing orders that apply a panel for all patients; reflex definitive testing when a presumptive point-of-care test has already been performed; physician standing orders that apply to all patients; billing separately for individual definitive test codes when those analytes are already included in an ordered panel; performing or ordering presumptive immunoassay testing from a reference laboratory without an appropriate physician order; and using immunoassay (IA) results from CLIA-waived devices (cups, dipsticks, cards, cassettes) as a basis for definitive testing when the presumptive test was not ordered per policy.

    Outpatient confirmatory/definitive quantitative drug testing that includes greater than or equal to 14 drugs/drug classes is considered not medically necessary. Requests that exceed this threshold do not meet the policy's medical necessity criteria.

    Screening asymptomatic patients is generally not medically necessary unless a specific covered indication is detailed elsewhere in the policy. Other listed situations that are NMN include use of testing for routine administrative exams, same-day multi-source screening across specimen types, and procedural or laboratory workflow scenarios described under the policy exclusions.

    Covered Indications

    Confirmatory/definitive testing when presumptive testing performed and results inconsistent with clinical picture, when provider expects a presumptive positive and quantitative levels inform management, or when serum therapeutic drug level is needed for medical treatment.

    Confirmatory/definitive testing is covered when presumptive testing has been performed and results warrant definitive analysis, when provider expects presumptive positive and quantitative levels will inform management, or when a serum therapeutic drug level is needed for medical treatment.

    When presumptive testing performed and inconsistent with clinical picture: Medical record documents history or suspicion of illicit or prescription misuse, noncompliance, or high probability of non-adherence; a prior preliminary/presumptive test was performed unless no reliable test exists; the presumptive result is inconsistent with expected clinical findings or drug-class specific assays are needed; resolving the inconsistency is essential to ongoing care; requested definitive testing targets fewer than 14 drug/drug classes and only the specific drugs indicated by the preliminary analysis; specific substance and/or quantity information is desired.<14 drugs/drug classes

    Aligns with criteria set A

    When provider expects presumptive positive and quantitative levels inform management: Provider expects a positive presumptive test (e.g., patient-reported recent use); established clinical decision-making benchmarks exist for specific substances/quantitative levels; requested tests are limited to fewer than 14 drugs/drug classes; and testing is limited to the specific drugs/drug classes expected to be positive.

    Coding

    CPT Codes That Support Coverage CriteriaCPTCovered
    0011UPrescription drug monitoring, evaluation by LC-MS/MS, oral fluid, reported as a comparison to an estimated steady-state range, per date of service
    80184Phenobarbital
    80320Alcohols
    80321Alcohol biomarkers; 1 or 2
    80322Alcohol biomarkers; 3 or more
    80323Alkaloids not otherwise specified
    80326Amphetamines; 5 or more
    80335Antidepressants, tricyclic and other cyclicals; 1 or 2
    80346Benzodiazepines; 1 to 12
    80354Fentanyl
    1–10 of 16
    1/2
    CPT Codes That Do Not Support Coverage CriteriaCPTNot Covered
    0054UPrescription monitoring; 14 or more classes/substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report
    0082UDefinitive test(s), 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive any number of drug classes
    0328UAssay, definitive, 120 or more drugs and metabolites, urine, quantitative LC-MS/MS
    HCPCS Codes That Support Coverage CriteriaHCPCSCovered
    G0480Definitive drug test(s), methods able to identify individual drugs and distinguish structural isomers, qualitative or quantitative, includes specimen validity testing, per 1 to 7 classes
    G0481Definitive drug test(s), methods able to identify individual drugs and distinguish structural isomers, qualitative or quantitative, includes specimen validity testing, per 8 to 14 drug classes
    HCPCS Codes That Support Coverage CriteriaHCPCSCovered
    G0480Drug test(s), definitive, utilizing methods able to identify individual drugs and distinguish between structural isomers; includes specimen validity testing; per 1 to 7 classes
    G0481Drug test(s), definitive, utilizing methods able to identify individual drugs and distinguish between structural isomers; includes specimen validity testing; per 8 to 14 classes
    HCPCS Codes That Do Not Support Coverage CriteriaHCPCSNot Covered
    G0482Drug test(s), definitive; per 15 to 21 classes (does not support coverage criteria in this policy)
    G0483Drug test(s), definitive; per 22 or more classes (does not support coverage criteria in this policy)
    Additional CPT/HCPCS codes noted in policy updatesmixed
    80367Added to coding tables supporting coverage criteria
    80368Added to coding tables supporting coverage criteria
    80369Added to coding tables supporting coverage criteria
    80370Added to coding tables supporting coverage criteria; description updated in background
    80372Added to coding tables supporting coverage criteria
    80373Added to coding tables supporting coverage criteria
    820772021 CPT-82077 added to list of codes that support coverage criteria
    0328UAdded to list of CPT codes that do not support coverage criteria
    0082UAdded to CPT codes that do not support coverage criteria
    CPT codes previously listed as not medically necessary / later removedCPTNot Covered
    0143UListed as not medically necessary (later removed when code deleted)
    0144UListed as not medically necessary (later removed when code deleted)
    0145UListed as not medically necessary (later removed when code deleted)
    0146UListed as not medically necessary (later removed when code deleted)
    0147UListed as not medically necessary (later removed when code deleted)
    0148UListed as not medically necessary (later removed when code deleted)
    0149UListed as not medically necessary (later removed when code deleted)
    0150UListed as not medically necessary (later removed when code deleted)
    Maximum number of drug classes for medical necessity
    Maximum allowed drug classes for definitive testingFewer than 14 drugs/drug classes (<14)
    Policy statement on excessive testingOutpatient confirmatory/definitive quantitative drug testing of more than 14 drugs/drug classes is not medically necessary.
    Applied whenRequested confirmatory tests must be for the specific drug(s) or drug classes indicated by preliminary analysis and be <14 classes.
    Drug class count thresholds (HCPCS)
    G0480Definitive drug test(s), includes specimen validity testing; per 1 to 7 drug class(es)

    Provider Actions & Requirements

    Prior Authorization

    Authorization timing and pediatric exemption

    Requests for authorization will be accepted up to 10 business days after specimen collection and will be reviewed for medical necessity based on the criteria in this policy. Testing for children 6 years of age and younger is exempt from prior authorization.

    • Authorization requests accepted up to 10 business days after specimen collection
    • Children age 6 and under: exempt from authorization
    Denial Risk

    Administrative-purpose testing excluded

    Urine or other drug testing is not medically necessary when performed for administrative purposes. Examples include but are not limited to employment or pre-employment screening, continuation-of-employment requirements, school or athletic program screening, court-ordered or other medico-legal screening (unless required by state law), insurance eligibility or licensure examinations, routine physicals, or other non-clinical administrative requirements. Blanket orders, routine standing orders for all patients in a practice, and screening asymptomatic patients for administrative reasons are not supported.

    Ordering Requirements

    Documentation Required

    Physician order required for presumptive and reflex definitive testing

    A physician order is required for presumptive testing to be performed and for reflexing to definitive testing; presumptive testing generally should precede definitive testing except when no reliable presumptive test exists.

    • Obtain and document a physician order before performing presumptive or reflex definitive testing.
    Note

    Presumptive test generally required before definitive; pediatric PA exemption

    A presumptive test is generally required before ordering definitive testing unless no reliable presumptive test exists; pediatric testing (≤6 years) is exempt from prior authorization requirements per the policy.

    • If no reliable presumptive test exists for the target substance (e.g., synthetic cannabinoids), definitive testing may be ordered without a presumptive test.
    • Testing for children 6 years of age is exempt from PA.

    Not Covered

    Comprehensive definitive testing panels that cover very large numbers of drug classes are listed as not supporting coverage. Examples of CPT codes representing such broad panels include 0054U, 0082U, and 0328U, which are cited in the policy as not supporting the coverage criteria.

    Definitive testing billed using HCPCS codes G0482 (per 15–21 classes) or G0483 (per 22 or more classes) does not support coverage criteria in this policy. The policy supports HCPCS G0480 and G0481 (1–7 and 8–14 classes, respectively) but explicitly excludes claims billed using G0482 or G0483 from meeting the coverage requirements.

    Definitions

    Definitive/Confirmatory testing — analytical methods
    DefinitionAnalytical methods (e.g., GC-MS, LC-MS/MS) used to specifically identify and/or quantify drugs or metabolites with high sensitivity and specificity, typically used to confirm presumptive immunoassay results.
    Analytic requirementsMethods able to identify individual drugs and distinguish structural isomers, using stable isotope/internal standards and method- or drug-specific calibration and matrix-matched quality control (per HCPCS descriptions).
    Common useUsed when preliminary/presumptive results are inconsistent with clinical picture or when quantitative substance information is needed to guide care.
    Presumptive/Preliminary testing
    DefinitionInitial screening tests, commonly immunoassays, that provide rapid, inexpensive detection but have higher risk of false positives and negatives and may require confirmatory testing.

    Background

    Drugs of abuse testing is used to monitor adherence to prescribed controlled substances and to detect misuse. Common initial presumptive/ screening methods are immunoassays (rapid, cost-effective but prone to false positives/negatives), while definitive/confirmatory testing employs analytic techniques such as GC‑MS or LC‑MS/MS to specifically identify and/or quantify drugs or metabolites with high sensitivity and specificity. Confirmatory testing is indicated when presumptive results are inconsistent with the clinical picture or when quantitative levels are needed to guide treatment.

    Frequency Limits

    Frequency limits — unspecified
    Status of frequency limitsNot specified in this portion of the document.
    Related guidancePolicy notes that presumptive drug testing limits for chronic opioid therapy were moved to CP.MP.208; definitive testing references those limits.
    Ordering implicationPhysician order required for presumptive testing and reflexing to definitive testing; presumptive testing generally should precede definitive testing unless no reliable test exists.
    Presumptive/definitive testing interplay
    Interplay summaryPresumptive drug testing limits (e.g., in chronic opioid therapy) were moved to a separate policy (CP.MP.208); this definitive testing policy references that presumptive/definitive interplay.
    Presumptive prerequisite

    Revision History

    2018-07-18criteria_revision

    Modified criteria to require a presumptive test before a definitive test unless no reliable test is in existence; added indication for testing when a presumptive test is assumed positive but quantitative levels are required.

    2019-05-01coding_and_text_clarification

    Revised I.A.1 wording from 'unless no reliable test is available' to 'unless no reliable test is in existence' and updated coding tables; stated that HCPCS codes G0482 and G0483 do not support coverage.

    2021-02-01policy_rename_and_structure_change
    Policy Summary
    PayerCentene
    PolicyDrugs of Abuse: Definitive Testing
    Policy CodePolicy CP.MP.50
    Change TypeCriteria and coding updatesauthorization protocol added
    Effective Date
    Next Review Date
    Key ActionObtain a presumptive test before ordering definitive testing unless no reliable presumptive test exists; submit PA within 10 business days when required (children ≤6 exempt).
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsCodingProvider Actions & RequirementsOrdering RequirementsNot CoveredDefinitionsBackgroundFrequency LimitsRevision History
    <14 drugs/drug classes

    Aligns with criteria set B

    When serum therapeutic drug level is required for treatment: Request is for a serum therapeutic level in relation to medical treatment of a disease or condition (example: phenobarbital level for seizure management).

    Aligns with criteria set C

    Definitive testing for individuals when clinically indicated and when presumptive testing has been performed and supports the need for definitive testing, or when no reliable presumptive test exists for the target drug(s).

    Clinically indicated definitive testing: Definitive testing is covered when clinically indicated and when a presumptive test has been performed and supports the need for definitive testing, or when no reliable presumptive test exists for the target drug(s). Definitive methods include those described in HCPCS G0480 (1–7 classes) and G0481 (8–14 classes) and include specimen validity testing.per HCPCS G0480/G0481 class counts

    Includes HCPCS descriptions

    G0481Definitive drug test(s), includes specimen validity testing; per 8 to 14 drug class(es)
    G0482Definitive drug test(s), includes specimen validity testing; per 15 to 21 drug class(es) — does NOT support coverage in this policy
    G0483Definitive drug test(s), includes specimen validity testing; per 22 or more drug class(es) — does NOT support coverage in this policy
    • Excluded uses: employment/pre-employment, school/athletic screening, medico-legal/court-ordered (unless mandated), insurance/licensure exams, routine physicals for administrative purposes
    • Also excluded: blanket orders, routine standing orders for all patients, asymptomatic screening for administrative reasons
    Documentation Required

    Medical record documentation required

    The medical record must document a history or clinical suspicion of illicit drug use or prescription medication misuse, noncompliance, or a high probability of non-adherence to a prescribed regimen. Documentation should include relevant clinical history, discussion of recent medication use with the member/enrollee, indications for testing, and how the test results will affect ongoing clinical management.

    • Documented history or suspicion of illicit or prescription misuse, noncompliance, or high probability of non-adherence
    • Record must include clinical history, discussion of recent medication/use, reason for testing, and impact on care
    Note

    Presumptive testing prerequisite

    A presumptive (preliminary/qualitative) test should generally be performed before ordering definitive/confirmatory testing. Definitive testing may be ordered without a prior presumptive test only when no reliable presumptive test exists for the substance in question (for example, certain synthetic cannabinoids) or when clinical circumstances make presumptive testing impractical.

    • Presumptive testing is a prerequisite for definitive testing unless no reliable presumptive test exists (e.g., some synthetic cannabinoids)
    • Definitive testing without a prior presumptive test is allowed when clinical circumstances or lack of reliable presumptive assays justify it
    Billing Rule

    Presumptive before definitive

    Definitive testing should be limited to the specific drug(s) or drug classes indicated by the presumptive test or by clinical suspicion. Reflex definitive testing following point-of-care presumptive testing is not supported when the presumptive test itself was already performed at point of care unless the coverage criteria for confirmatory testing are met and documentation supports the need for definitive identification or quantification.

    • Definitive tests must target the specific drug(s)/classes indicated by the presumptive test or clinical scenario
    • Reflex definitive testing after point-of-care presumptive testing is a denial risk unless criteria for confirmatory testing are met and documented
    Typical examples
    Point-of-care urine immunoassay cups, dipsticks, cards, cassettes used for preliminary screening.
    Policy roleA preliminary/presumptive drug test is generally required before definitive testing unless no reliable presumptive test exists (e.g., synthetic cannabinoids).
    Definitive testing (per HCPCS descriptions)
    HCPCS description (general)Analytic methods able to identify individual drugs and distinguish structural isomers using techniques such as GC-MS and LC-MS with stable isotope/internal standards and method-specific calibration and matrix-matched quality control; includes specimen validity testing.
    Intended reportingQualitative or quantitative results; includes specimen validity testing and per-class reporting as specified by HCPCS codes.
    Exclusion of immunoassaysHCPCS definitions explicitly exclude immunoassays (eg, IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods.
    Definitive testing (limited classes)
    G0480 scopeDefinitive testing described per 1 to 7 drug classes (per HCPCS G0480).
    G0481 scopeDefinitive testing described per 8 to 14 drug classes (per HCPCS G0481).
    Higher-class codesHCPCS codes for higher class counts (G0482, G0483) represent 15+ classes and do not support coverage under this policy.
    Policy requires a presumptive test generally be performed before definitive testing unless no reliable presumptive test exists.
    Administrative notePresumptive testing criteria were removed from this policy and placed in CP.MP.208 during revision.
    Latest

    Renamed policy to 'Drugs of Abuse: Definitive Testing' and removed presumptive testing criteria into a new separate policy (CP.MP.208); removed previous UM language about PA exemption for children <6 and 10-day post-test PA window.